-
Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to Bring Its Cancer Meds to the World
25 Jan 2025 00:45 GMT
… available, such as the Novartis drugs Scemblix and Gleevec. … therapies, Ascentage said in its IPO filing. Furthermore, first- and … cancers developed resistance to the Novartis drugs.
“In a five … period,” Ascentage said in the IPO filing. “Therefore, we believe …
-
Ascentage prices first biotech IPO of 2025, raising $126M
24 Jan 2025 05:17 GMT
… the first U.S. initial public offering by a biotechnology company … similar drugs, such as Novartis’ Gleevec and Scemblix, are … Ascentage said in its IPO prospectus.
A second Ascentage … outlined IPO plans in January.
Overall, however, biotech IPOs have …
-
Rx Rundown: Sanofi, Bristol Myers Squibb, Omega Therapeutics and more
07 Feb 2025 13:05 GMT
… is eyeing a $135 million initial public offering.
Radiopharmaceuticals biotech AdvanCell raised a … to its latest earnings report.
Novartis posted better-than-expected Q4 …
-
2024: A Year of Cautious IPOs, Restraint and Breakthroughs
18 Dec 2024 14:52 GMT
… knew the answer: IPOs. Everything was IPOs all the time. Fewer … following the pandemic’s IPO boom. Will the window … favorite buyout of 2024 was Novartis’ acquisition of neuromuscular disease … still in preclinical development. Novartis’ interest in the company …
-
Swiss pharma giant Novartis says 30 pipeline drugs with ‘significant potential’ will drive long-term growth
21 Nov 2024 13:00 GMT
Swiss pharmaceutical giant Novartis on Thursday lifted its … between 2024 and 2030.
“Novartis has completed its transformation into … in 2023, also through an IPO.
Such moves have seen the … neuroscience and oncology.
Shares in Novartis edged ahead 0.3 percent …
-
Novartis Slumps On Lagging Sales Of Its Biggest Moneymaker
29 Oct 2024 14:17 GMT
… .92, according to MarketSurge. Novartis stock is also losing support … were expecting one."
Novartis put up several strong numbers … -double-digit percentage. Previously, Novartis guided sales to high-single … To Buy And Watch: Top IPOs, Big And Small Caps, …
-
7 Reasons Why Hyundai’s IPO Failed: From Premium Listing To Nationalism, How Indian Investors Rejected The South Korean Chaebol’s Attempt to Milk India!
20 Oct 2024 09:34 GMT
… keeping investors away from the IPO.
External competition.
The Korean … companies. Following the Hyundai IPO, more Korean chaebols (family … market, and now that Novartis and ITD Cementation are looking … listing gains seen in other IPOs in recent months. Despite …
-
CellBion eyes global expansion in radiopharmaceuticals after Kosdaq IPO
26 Sep 2024 06:41 GMT
CellBion, a Korean developer of radioisotope-based cancer therapeutics, announced its plans for global growth following its recent Kosdaq listing. At a press conference on Wednesday, CEO Kim Kweon outlined the company's vision to develop new …
-
CeriBell IPO Features Revenue Growth But High Operating Losses
30 Aug 2024 18:12 GMT
… and Senior Strategy Manager at Novartis. Seizures in a hospital … 32.3 million). CeriBell’s IPO And Valuation Details CeriBell intends … companies have performed poorly post-IPO. CeriBell said it will … learn more information about the IPO’s pricing and valuation …
-
Adlai Nortye Ltd. Announces Pricing of Initial Public Offering
29 Sep 2023 06:46 GMT
… announced the pricing of its initial public offering of 2,500,000 American … companies such as Eisai and Novartis, to fully realize the potential … with respect to the proposed initial public offering and the concurrent private placement …